Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Terumo Applies for Left Ventricular Assist System
October 19, 2009
- Astellas to Apply for IBS in Women as Addn'l Indication for Irribow
October 19, 2009
- Some Healthcare Professionals Don't Recommend Use of Relief System to Their Patients to Save Time
October 19, 2009
- JPMA to Stress Value of New Drugs on TV
October 19, 2009
- BioJapan 2009
October 19, 2009
- Multaq Recommended for Approval in the EU: sanofi-aventis
October 19, 2009
- Takeda Introduces "Mutual Consent System" for Decision Making
October 19, 2009
- Mylan to Develop Cysteamine, Zeria Oral Phosphate
October 19, 2009
- Kowa Licenses Livalo to Algorithm in the Middle East, North Africa
October 19, 2009
- Disappointment Prevails at JPMA Seminar on Development of Unapproved Drugs
October 19, 2009
- Sanwa Kagaku Licenses FYX-051 from Fuji Yakuhin
October 19, 2009
- Korosho to Continue to Support Development of Unapproved Drugs via Non-budgetary Measures
October 19, 2009
- Meiji Seika Aims at Top-3 Position in CNS
October 19, 2009
- No More Problems with Speed or Quality of Clinical Trials in Japan: Korosho's WG
October 19, 2009
- Daiichi Sankyo to Make Vaccines One of Its Core Businesses
October 19, 2009
- R&D NEWS IN BRIEF
October 19, 2009
- New Drugs Account for 13% of Total Sales: Novartis
October 19, 2009
- Sandoz's Somatropin Equivalent to Original Product: Mr Nakamichi
October 19, 2009
- Sales Force Effectiveness Summit Japan 2009
October 19, 2009
- JSGM to Propose Standard Prescription Ordering Form
October 19, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…